Mizuho started coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a report released on Monday, Marketbeat.com reports. The brokerage issued a neutral rating and a $26.00 price target on the biotechnology company’s stock.
Several other research analysts also recently issued reports on the stock. Wedbush raised their price objective on shares of Audentes Therapeutics to $56.00 and gave the stock an outperform rating in a research report on Thursday, January 4th. Zacks Investment Research downgraded shares of Audentes Therapeutics from a hold rating to a sell rating in a research report on Friday, November 17th. BidaskClub downgraded shares of Audentes Therapeutics from a strong-buy rating to a buy rating in a research report on Wednesday, December 6th. Leerink Swann reissued an outperform rating and set a $29.00 price objective (up from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday, November 15th. Finally, HC Wainwright set a $37.00 target price on shares of Audentes Therapeutics and gave the company a buy rating in a report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Audentes Therapeutics presently has a consensus rating of Buy and a consensus target price of $34.00.
Shares of Audentes Therapeutics (NASDAQ BOLD) traded up $1.47 during trading on Monday, reaching $34.29. 203,100 shares of the company’s stock traded hands, compared to its average volume of 538,700. Audentes Therapeutics has a 52 week low of $13.90 and a 52 week high of $41.80.
Large investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new stake in shares of Audentes Therapeutics in the third quarter valued at about $143,000. Teacher Retirement System of Texas purchased a new stake in Audentes Therapeutics during the fourth quarter worth about $208,000. MetLife Investment Advisors LLC purchased a new stake in Audentes Therapeutics during the fourth quarter worth about $248,000. Nationwide Fund Advisors boosted its holdings in Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after buying an additional 6,384 shares in the last quarter. Finally, Trexquant Investment LP purchased a new stake in Audentes Therapeutics during the third quarter worth about $295,000. 64.94% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first published by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/audentes-therapeutics-bold-coverage-initiated-by-analysts-at-mizuho/1885975.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.